Hepatitis B core protein allosteric modulators

A compound represented by:

• wherein
• Y is S(O)y, wherein y is 2;
• Rm′ and Rm are each independently selected from the group consisting of H, halogen, C1-6 alkyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), C2-6 alkenyl (optionally substituted by one, two or three substituents each independently selected from halogen and hydroxyl), NR′R″, and hydroxyl;
• Rc is H;
• R78 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, NR′R″, —C(O)—C1-6 alkyl, —C(O)—C1-6 alkoxy, phenyl, heteroaryl, C3-6 cycloalkyl, —S(O)w—C1-6 alkyl (where w is 1, 2 or 3), —S(O)w—NR′R″ (where w is 1, 2 or 3), and —NR′—S(O)w, (where w is 1, 2 or 3));
• R79 is selected from the group consisting of H, halogen, hydroxyl, nitro, cyano, carboxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, NR′R″, —C(O)—C1-6 alkyl, —C(O)—C1-6 alkoxy, phenyl, heteroaryl, C3-6 cycloalkyl, —S(O)w—C1-6 alkyl (where w is 1, 2 or 3), —S(O)w—NR′R″ (where w is 1, 2 or 3), and —NR′—S(O)w, (where w is 1, 2 or 3));
• R′ is selected, independently for each occurrence, from H, methyl, ethyl, and propyl;
• R″ is selected, independently for each occurrence, from H, methyl, ethyl, propyl, butyl, C(O)-methyl and —C(O)-ethyl, or R′ and R″ taken together with the nitrogen to which they are attached may form a 4-6 membered heterocycle;
• each of moieties R4, R5, R6, R7, R8, R9, and R10 is independently selected for each occurrence from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkynyl, C2-6 alkenyl, halogen, hydroxyl, nitro, cyano, and NR′R″;
• wherein for each occurrence, C1-6 alkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, NR′R″, —NR′—S(O)w, and S(O)w—NR′R″;
• C1-6 alkoxy may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C1-6 alkyl, NR′R″, —NR′—S(O)w, and S(O)w—NR′R″;
• C3-6 cycloalkyl may be optionally substituted with one, two, three or more substituents selected from the group consisting of halogen, hydroxyl, nitro, cyano, carboxy, C1-6 alkyl, C1-6 alkoxy, —C(O)—C1-6 alkyl, —C(O)—C1-6 alkoxy, and NR′R″;
• phenyl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, NR′R″, C(O)—NR′R″, —C(O)—C1-6 alkyl, —C(O)—C1-6 alkoxy, —S(O)w—C1-6 alkyl (where w is 1, 2 or 3), NR′—S(O)w, and —S(O)w—NR′R″ (where w is 1, 2 or 3), and heteroaryl may be optionally substituted by one, two or three substituents each independently selected from the group consisting of halogen, hydroxyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-6 alkoxy, NR′R″, C(O)—NR′R′—C(O)—C1-6 alkyl, —C(O)—C1-6 alkoxy, —S(O)w—C1-6 alkyl (where w is 1, 2 or 3), NR′—S(O)w, and —S(O)w—NR′R″(where w is 1, 2 or 3), and pharmaceutically acceptable salts thereof.